Patient Characteristics and Treatment Patterns in European Pediatric Patients with Psoriasis: A Real-World, Cross-Sectional Study

Abstract

Introduction: This study evaluated patient characteristics and treatment patterns according to weight in pediatric patients with psoriasis in a real-world setting. Methods: Primary care and specialist physicians treating pediatric patients with psoriasis aged 6-17 years in five European countries were surveyed in the 2019-2020 Adelphi Real World Pediatric Psoriasis Disease Specific Programme. At least two patients with current or previous biologic use were included per physician. Patient characteristics and treatment patterns were analyzed overall and for patients weighing 25-50 kg or more than 50 kg. Results: Data from 772 patients weighing 25-50 kg and 1147 weighing more than 50 kg were analyzed. Median age at diagnosis was significantly less in lighter than heavier patients (10.0 vs. 14.0 years; p \ 0.001), as was median disease duration (2.2 vs. 3.0 years; p \ 0.001). Topical treatments were prescribed in 59.0% of patients overall (70.3% of lighter and 51.4% of heavier patients; p \ 0.001), and were used to

Vaikų Psoriazė − Gydymo Iššūkiai Ir Galimybės

“…Biologinė terapija. Europoje vidutinio sunkumo ir sunkiai vaikų psoriazei gydyti šiuo metu patvirtinta keletas biologinių vaistų (etanerceptas, adalimumabas, ustekinumabas) įskaitant ir naujesnius biologinius vaistus (iksekizumabas ir secukinumabas) [16]. Tiriami ir kiti biologiniai preparatai, tokie kaip brodalumabas [17], guselkumabas [18] ir risankizumabas [19].…”

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability

“…Biologics are more likely to be prescribed in patients with moderate-to-severe PsO, overweight and with concomitant psoriatic arthritis. 32 Approximately 25% of pediatric patients with psoriasis are treated with biologics at some point in their life, and one-third of them will also simultaneously receive topical and/or conventional treatment. 32 The real-life study conducted among psoriatic patients by Marques et al 33 which included also children revealed superior effectiveness of biological medications when compared to topical and non-biological therapies, but higher rate of side effects including mild infections, which are consistent with other studies.…”

“… 32 Approximately 25% of pediatric patients with psoriasis are treated with biologics at some point in their life, and one-third of them will also simultaneously receive topical and/or conventional treatment. 32 The real-life study conducted among psoriatic patients by Marques et al 33 which included also children revealed superior effectiveness of biological medications when compared to topical and non-biological therapies, but higher rate of side effects including mild infections, which are consistent with other studies. 34 European recommendations emphasize that choosing biologics for patients should be influenced by specific circumstances, such as presence of comorbidities, pregnancy or chronic infections.…”